Do you know about targeted therapy for colon cancer? Targeted therapy for colon cancer is a question for many patients, and targeted therapy for colon cancer has been concerned for a long time. Nowadays, not many people know about targeted therapy for colon cancer, so let’s learn more about targeted therapy for colon cancer below. At present, there are various molecular colon cancer targeted therapy drugs used in the treatment of tumors. In the treatment of colon cancer (crc), there are mainly three different targeted therapies as follows, and they have achieved unique efficacy. Phase 2 and 3 trials are evaluating the role of epidermal growth factor receptor (egfr) inhibitors, vascular endothelial growth factor receptor (vegfr) inhibitors, and cyclooxygenase (cox 2) inhibitors in the treatment of this disease. Encouraging clinical results have been obtained regarding the use of cetuximab and bevacizumab in the treatment of stage 3/4 colorectal cancer, especially when they are combined with irinotecan-based regimens. Targeted therapy for colorectal cancer has been demonstrated by the efficacy of cetuximab in combination with irinotecan in the bond study, and cetuximab is one of the most effective agents for the treatment of acrc. Bevacizumab combined with irinotecan-based ifl regimens have demonstrated improved survival over ifl regimens alone in chemotherapy-insensitive acrc patients. Cyclooxygenase 2 (cox) inhibitors, which prevent adenomatous polyps from turning malignant, and other clinical studies have found that they may play a role in adjuvant therapy. The above is the introduction of targeted therapy for colon cancer. We hope that after reading this, we can understand the problems of targeted therapy for colon cancer and pay attention to any problems related to targeted therapy for colon cancer, please follow the medical advice for specific targeted therapy for colon cancer!